Court ruling likely to boost spirits and ultimately transactions in the sector
Source
Author: unknown
Healthcare M&A: Titans on spree as regulatory crackdown falls flat [Mergers & Acquisitions]
Related Posts
AbbVie’s $1.4B Alzheimer’s Bet: Game Changer or Risky Gamble?
Strategic Acquisition: AbbVie's $1.4 billion acquisition of Aliada Therapeutics signals a significant bet on Alzheimer's disease treatment, bolstering its pipeline with a Phase I anti-amyloid...
Roche vs. Novo-Catalent Deal: Shaping Pharma’s Competitive Future
Competitive Landscape: Roche CEO Thomas Schinecker urges regulators to block Novo Holdings' $16.5B acquisition of Catalent, citing concerns over reduced competition and potential negative impacts on...
Starboard Challenges Pfizer: Demands Accountability in M&A and R&D
Activist Investor Scrutiny: Starboard Value, a prominent activist investor, is calling for greater accountability from Pfizer's leadership over perceived overpaid M&A deals and poor returns on R&D...
Eye Care Giant Bausch + Lomb: $10B Debt Financing Bid Heats Up
Competitive Bidding Frenzy: Banks and private credit firms are engaged in an intense bidding war to secure a $5 billion debt financing deal for Bausch + Lomb, a prominent player in the eye care...